Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Ramucirumab vs Chemotherapy in PD-L1-positive Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
CTR20202468Phase 3Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Innovent Biologics. Started Dec 2020; status: terminated.
02
Drugs
sintilimabramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20202468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202468.